<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37128806</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-2165</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of cosmetic dermatology</Title><ISOAbbreviation>J Cosmet Dermatol</ISOAbbreviation></Journal><ArticleTitle>Hyaluronic acid-based fillers in patients with autoimmune inflammatory diseases.</ArticleTitle><Pagination><StartPage>2420</StartPage><EndPage>2423</EndPage><MedlinePgn>2420-2423</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jocd.15751</ELocationID><Abstract><AbstractText>The use of hyaluronic acid (HA)-based aesthetic therapies is growing steadily, and according to the International Society of Aesthetic Plastic Surgery, more than 4.3 million aesthetic procedures using HA were performed in 2019, an increase of 15.7% than 2018. More people are offering these types of services, often without proper training or qualifications. Therefore, there is an increasing number of reports in the literature relating to possible adverse events, with subsequent therapeutic problems and more or less serious consequences for patients. The aim of this research is to carry out a review of the literature in order to evaluate the impact of hyaluronic acid-based fillers in patients with autoimmune inflammatory diseases, in particular scleroderma and Systemic Lupus Erythematosus (SLE). Although HA plays a central role in the inflammatory process, the use of HA-based fillers in patients with autoimmune inflammatory diseases is still controversial. HA, in fact, in inflamed tissues helps to propagate the inflammatory response and, injected in the form of a dermal filler, could potentially promote reactivation of the underlying disease. For this reason, many specialists do not perform HA-based aesthetic treatments in patients with scleroderma or SLE. However, recent scientific evidence suggests that the use of HA-based fillers in patients with scleroderma can lead to improvement of skin lesions, with satisfactory results. In the literature, there are no clinical studies that contraindicate the administration of HA-based dermal fillers in patients with inflammatory disease.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pieretti</LastName><ForeName>Gorizio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Multidisciplinary Department of Medical Surgery and Dental Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rafaniello</LastName><ForeName>Concetta</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraenza</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donniacuo</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuomo</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8396-095X</Identifier><AffiliationInfo><Affiliation>M.D. Plastic Surgery Unit - Department of Medicine, Surgery and Neuroscience - University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzano</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>M.D. Plastic and Reconstructive Surgery Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccarelli</LastName><ForeName>Feliciano</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>M.D. Plastic Surgery Unit, Villa dei Fiori, Acerra, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capuano</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicoletti</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Multidisciplinary Department of Medical Surgery and Dental Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cosmet Dermatol</MedlineTA><NlmUniqueID>101130964</NlmUniqueID><ISSNLinking>1473-2130</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9004-61-9</RegistryNumber><NameOfSubstance UI="D006820">Hyaluronic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067548">Dermal Fillers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006820" MajorTopicYN="N">Hyaluronic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003357" MajorTopicYN="Y">Cosmetic Techniques</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013518" MajorTopicYN="Y">Surgery, Plastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012060" MajorTopicYN="N">Rejuvenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067548" MajorTopicYN="Y">Dermal Fillers</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37128806</ArticleId><ArticleId IdType="doi">10.1111/jocd.15751</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Gualdi G, Monari P, Cammalleri D, Pelizzari L, Calzavara-Pinton P. Hyaluronic acid-based products are strictly contraindicated in scleroderma-related skin ulcers. Wounds. 2019;31(3):81-84.</Citation></Reference><Reference><Citation>Owczarczyk-Saczonek A, Zdanowska N, Wygonowska E, Placek W. The immunogenicity of hyaluronic fillers and its consequences. Clin Cosmet Investig Dermatol. 2021;14:921-934.</Citation></Reference><Reference><Citation>Micheels P, Besse S, Flynn TC, Sarazin D, Elbaz Y. Superficial dermal injection of hyaluronic acid soft tissue fillers: comparative ultrasound study. Dermatol Surg. 2012;38(7 Pt 2):1162-1169. doi:10.1111/j.1524-4725.2012.02471.x</Citation></Reference><Reference><Citation>Fagien S, Bertucci V, von Grote E, Mashburn JH. Rheologic and physicochemical properties used to differentiate injectable hyaluronic acid filler products. Plast Reconstr Surg. 2019;143(4):707e-720e. doi:10.1097/PRS.0000000000005429</Citation></Reference><Reference><Citation>De Boulle K, Heydenrych I. Patient factors influencing dermal filler complications: prevention, assessment, and treatment. Clin Cosmet Investig Dermatol. 2015;8:205-214.</Citation></Reference><Reference><Citation>Lee-Sayer SS, Dong Y, Arif AA, Olsson M, Brown KL, Johnson P. The where, when, how, and why of hyaluronan binding by immune cells. Front Immunol. 2015;6:150.</Citation></Reference><Reference><Citation>Suarez-Fueyo A, Tsokos MG, Kwok SK, et al. Hyaluronic acid synthesis contributes to tissue damage in systemic lupus erythematosus. Front Immunol. 2019;10:2172.</Citation></Reference><Reference><Citation>Cumsky HJL, Michael M, Hoss E. Use of botulinum toxin and hyaluronic acid filler to treat oral involvement in scleroderma. Dermatol Surg. 2022;48(6):698-699.</Citation></Reference><Reference><Citation>Sharad J. Hyaluronic acid filler injection for localized scleroderma-case report and review of literature on filler injections for localized scleroderma. Clin Cosmet Investig Dermatol. 2022;15:1627-1637.</Citation></Reference><Reference><Citation>Philipp-Dormston WG, Hilton S, Nathan M. A prospective, open-label, multicenter, observational, postmarket study of the use of a 15 mg/mL hyaluronic acid dermal filler in the lips. J Cosmet Dermatol. 2014;13(2):125-134. doi:10.1111/jocd.12085</Citation></Reference><Reference><Citation>Creadore A, Watchmaker J, Maymone MBC, Pappas L, Vashi NA, Lam C. Cosmetic treatment in patients with autoimmune connective tissue diseases: best practices for patients with lupus erythematosus. J Am Acad Dermatol. 2020;83(2):343-363.</Citation></Reference><Reference><Citation>Pirrello R, Verro B, Grasso G, et al. Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study. Arthritis Res Ther. 2019;21(1):286.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>